| 产品详情 |
| Edit |   |
|---|
| Product Name | MLN9708 |
|---|
| Description | Purity >95%. MLN9708 is an orally bioavailable prodrug of the second-generation proteasome inhibitor MLN2239 . This prodrug rapidly hydrolyzes in plasma to the biologically active form, which inhibits the Beta5 chymotryptic-like subunit of the 20S proteasome (IC50 = 3.4 nM; Ki = 0.93 nM in cell-free assays). It inhibits the Beta1 caspase-like and Beta2 trypsin-like proteolytic sites with IC50 values of 0.03 and 3.5 µM, respectively. MLN9708 has shown antitumor activity both in cell-based assays and in xenograft models and has been examined in phase III clinical trials for potential antimyeloma activity. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 4-carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid, Ixazomib Citrate |
|---|
| Gene, Accession, CAS # | CAS: 1201902-80-8 |
|---|
| Catalog # | LS-H8770 |
|---|
| Price | |
|---|
| Order / More Info | MLN9708 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|